Dr. Huang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
801 Broadway
Ste 824
Seattle, WA 98122Phone+1 206-292-7990Fax+1 206-215-4550
Education & Training
- University of ChicagoFellowship, Cardiovascular Disease, 1995 - 1999
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1992 - 1995
- Northwestern University The Feinberg School of MedicineClass of 1992
Certifications & Licensure
- WA State Medical License 1999 - 2026
- IL State Medical License 1995 - 1999
- American Board of Internal Medicine Cardiovascular Disease
- American Board of Internal Medicine Interventional Cardiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System Start of enrollment: 2012 Dec 01
- An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) Start of enrollment: 2013 Feb 20
Publications & Presentations
PubMed
- 61 citationsImpact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States.Santiago Garcia, Larissa Stanberry, Christian W. Schmidt, Scott Sharkey, Michael Megaly
Catheterization and Cardiovascular Interventions. 2021-08-01 - 3 citationsDifferential Use and Impact of Bleeding Avoidance Strategies on Percutaneous Coronary Intervention-Related Bleeding Stratified by Predicted RiskTy J. Gluckman, Lian Wang, Kateri J. Spinelli, John L. Petersen, Paul Huang
Circulation. Cardiovascular Interventions. 2020-06-01 - 143 citationsA Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure.Emerson C. Perin, Kenneth M. Borow, Guilherme V. Silva, Anthony N. DeMaria, Oscar C. Marroquin
Circulation Research. 2015-08-28
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: